ACQUIRED · 2024
Who Acquired Ascend Clinical?
Eurofins Scientific · $165.7M· 11.2× EBITDA
The acquisition
Ascend Clinical was acquired by Eurofins Scientific in 2024 for $165.7M. The deal was priced at 11.2× EBITDA / 2.20× revenue.
Ascend Clinical at time of acquisition
Revenue
$76.1M
EBITDA
$14.7M
Deal value
$165.7M
EV / EBITDA
11.2×
Similar laboratory services acquisitions
- GeneSeek (Neogen Animal Genomics) · acquired by Zoetis in 2026 · $160.0M
- CHS Outreach Laboratory Assets · acquired by Laboratory Corporation of America Holdings in 2025 · $194.5M
- OPKO / BioReference Health (Clinical Diagnostics Business) · acquired by Labcorp in 2025 · $192.5M
- Akoya Biosciences, Inc. · acquired by Quanterix Corporation in 2025 · $286.0M
- Enzo Biochem, Inc. · acquired by Battery Ventures in 2025 · $37.0M
Run a valuation for a similar laboratory services business
Three fields, instant range, backed by 25,592 real M&A transactions including this one.
Open the laboratory services calculator →More on laboratory services valuations
- Laboratory Services valuation calculator· head-term variant
- Laboratory Services median multiples· real-deal benchmarks
- How to value a laboratory services· long-form guide
Sourced from Press releases and financial statements. Full deal page.
Citation: ExitValue.ai. (2024). Ascend Clinical acquired by Eurofins Scientific. https://exitvalue.ai/acquired/ascend-clinical